

**DEPARTMENT OF JUSTICE****Drug Enforcement Administration****[Docket No. DEA-392]****Bulk Manufacturer of Controlled Substances Application: American Radiolabeled Chem****ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before August 20, 2018.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of

manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division ("Assistant Administrator") pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.33(a), this is notice that on March 13, 2018, American Radiolabeled Chem, 101 Arc Drive, St. Louis, MO 63146 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Controlled substance	Drug code	Schedule
Gamma Hydroxybutyric Acid .....	2010	I
l-bogaine .....	7260	I
Lysergic acid diethylamide .....	7315	I
Tetrahydrocannabinols .....	7370	I
Dimethyltryptamine .....	7435	I
1-[1-(2-Thienyl)cyclohexyl]piperidine .....	7470	I
Dihydromorphine .....	9145	I
Heroin .....	9200	I
Normorphine .....	9313	I
Amphetamine .....	1100	II
Methamphetamine .....	1105	II
Amobarbital .....	2125	II
Phencyclidine .....	7471	II
Phenylacetone .....	8501	II
Cocaine .....	9041	II
Codeine .....	9050	II
Dihydrocodeine .....	9120	II
Oxycodone .....	9143	II
Hydromorphone .....	9150	II
Ecgonine .....	9180	II
Hydrocodone .....	9193	II
Meperidine .....	9230	II
Metazocine .....	9240	II
Methadone .....	9250	II
Dextropropoxyphene, bulk (non-dosage forms) .....	9273	II
Morphine .....	9300	II
Oripavine .....	9330	II
Thebaine .....	9333	II
Oxymorphone .....	9652	II
Phenazocine .....	9715	II
Carfentanil .....	9743	II
Fentanyl .....	9801	II

The company plans to manufacture small quantities of the above-listed controlled substances as radiolabeled compounds for biochemical research.

Dated: June 12, 2018.

**John J. Martin,**

*Assistant Administrator.*

[FR Doc. 2018-13231 Filed 6-19-18; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE****Drug Enforcement Administration****[Docket No. DEA-392]****Bulk Manufacturer of Controlled Substances Application: Cerilliant Corporation****ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before August 20, 2018.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA **Federal Register** Representative/DRW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers,

importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been delegated to the Assistant Administrator

of the DEA Diversion Control Division ("Assistant Administrator") pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.33(a), this is notice that on May

4th, 2018, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78665 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Controlled substance	Drug code	Schedule
3-Fluoro-N-methylcathinone (3-FMC) .....	1233	I
Cathinone .....	1235	I
Methcathinone .....	1237	I
4-Fluoro-N-methylcathinone (4-FMC) .....	1238	I
Pentedrone ( $\alpha$ -methylaminovalerophenone) .....	1246	I
Mephedrone (4-Methyl-N-methylcathinone) .....	1248	I
4-Methyl-N-ethylcathinone (4-MEC) .....	1249	I
Naphyrone .....	1258	I
N-Ethylamphetamine .....	1475	I
N,N-Dimethylamphetamine .....	1480	I
Fenethylamine .....	1503	I
Aminorex .....	1585	I
4-Methylaminorex (cis isomer) .....	1590	I
Gamma Hydroxybutyric Acid .....	2010	I
Methaqualone .....	2565	I
JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole) .....	6250	I
SR-18 (Also known as RCS-8) (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole) .....	7008	I
ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) .....	7010	I
5-Fluoro-UR-144 and XLR11 [1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone .....	7011	I
AB-FUBINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) .....	7012	I
JWH-019 (1-Hexyl-3-(1-naphthoyl)indole) .....	7019	I
MDMB-FUBINACA (Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) .....	7020	I
FUB-AMB, MMB-Fubinaca 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate .....	7021	I
AB-PINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) .....	7023	I
THJ-2201 [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone .....	7024	I
AB-CHMINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide) .....	7031	I
MAB-CHMINACA (N-(1-amino-3,3dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide) .....	7032	I
5F-AMB (Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate) .....	7033	I
5F-ADB; 5F-MDMB-PINACA (Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) .....	7034	I
ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) .....	7035	I
MDMB-CHMICA, MMB-CHMINACA (Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate) .....	7042	I
APINACA and AKB48 N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide .....	7048	I
5F-APINACA, 5F-AKB48 (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide) .....	7049	I
JWH-081 (1-Pentyl-3-(1-(4-methoxynaphthoyl) indole) .....	7081	I
SR-19 (Also known as RCS-4) (1-Pentyl-3-[(4-methoxy)-benzoyl]indole) .....	7104	I
JWH-018 (also known as AM678) (1-Pentyl-3-(1-naphthoyl)indole) .....	7118	I
JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole) .....	7122	I
UR-144 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone .....	7144	I
JWH-073 (1-Butyl-3-(1-naphthoyl)indole) .....	7173	I
JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) .....	7200	I
AM2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indole) .....	7201	I
JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole) .....	7203	I
PB-22 (Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate) .....	7222	I
5F-PB-22 (Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate) .....	7225	I
Alpha-ethyltryptamine .....	7249	I
CP-47,497 (5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl-phenol) .....	7297	I
CP-47,497 C8 Homologue (5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl-phenol) .....	7298	I
Lysergic acid diethylamide .....	7315	I
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) .....	7348	I
Marihuana .....	7360	I
Tetrahydrocannabinols .....	7370	I
Parahexyl .....	7374	I
Mescaline .....	7381	I
2-(4-Ethylthio-2,5-dimethoxyphenyl) ethanamine (2C-T-2) .....	7385	I
3,4,5-Trimethoxyamphetamine .....	7390	I
4-Bromo-2,5-dimethoxyamphetamine .....	7391	I
4-Bromo-2,5-dimethoxyphenethylamine .....	7392	I
4-Methyl-2,5-dimethoxyamphetamine .....	7395	I
2,5-Dimethoxyamphetamine .....	7396	I
JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole) .....	7398	I
2,5-Dimethoxy-4-ethylamphetamine .....	7399	I
3,4-Methylenedioxyamphetamine .....	7400	I
5-Methoxy-3,4-methylenedioxyamphetamine .....	7401	I
N-Hydroxy-3,4-methylenedioxyamphetamine .....	7402	I
3,4-Methylenedioxy-N-ethylamphetamine .....	7404	I
3,4-Methylenedioxyamphetamin .....	7405	I

Controlled substance	Drug code	Schedule
4-Methoxyamphetamine	7411	I
5-Methoxy-N-N-dimethyltryptamine	7431	I
Alpha-methyltryptamine	7432	I
Bufotenine	7433	I
Diethyltryptamine	7434	I
Dimethyltryptamine	7435	I
Psilocybin	7437	I
Psilocyn	7438	I
5-Methoxy-N,N-diisopropyltryptamine	7439	I
N-Ethyl-1-phenylcyclohexylamine	7455	I
1-(1-Phenylcyclohexyl)pyrrolidine	7458	I
1-[1-(2-Thienyl)cyclohexyl]piperidine	7470	I
N-Benzylpiperazine	7493	I
4-Methyl-alpha-pyrrolidinopropiophenone (4-MePPP)	7498	I
2-(2,5-Dimethoxy-4-methylphenyl) ethanamine (2C-D)	7508	I
2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine (2C-E)	7509	I
2-(2,5-Dimethoxyphenyl) ethanamine (2C-H)	7517	I
2-(4-iodo-2,5-dimethoxyphenyl) ethanamine (2C-I)	7518	I
2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine (2C-C)	7519	I
2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine (2C-N)	7521	I
2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine (2C-P)	7524	I
2-(4-Isopropylthio)-2,5-dimethoxyphenyl) ethanamine (2C-T-4)	7532	I
MDPV (3,4-Methylenedioxypropylvalerone)	7535	I
2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25B-NBOMe)	7536	I
2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25C-NBOMe)	7537	I
2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25I-NBOMe)	7538	I
Methylone (3,4-Methylenedioxy-N-methylcathinone)	7540	I
Butylone	7541	I
Pentylone	7542	I
alpha-pyrrolidinopentiophenone ( $\alpha$ -PVP)	7545	I
alpha-pyrrolidinobutiophenone ( $\alpha$ -PBP)	7546	I
AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole)	7694	I
Acetyldihydrocodeine	9051	I
Benzylmorphine	9052	I
Codeine-N-oxide	9053	I
Desomorphine	9055	I
Codeine methylbromide	9070	I
Dihydromorphine	9145	I
Heroin	9200	I
Hydromorphenol	9301	I
Methyldesorphine	9302	I
Methyldihydromorphine	9304	I
Morphine methylbromide	9305	I
Morphine methylsulfonate	9306	I
Morphine-N-oxide	9307	I
Normorphine	9313	I
Pholcodine	9314	I
U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide)	9547	I
AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide)	9551	I
MT45	9560	I
Acetylmethadol	9601	I
Allylprodine	9602	I
Alphacetylmethadol except levo-alphacetylmethadol	9603	I
Alphameprodine	9604	I
Alphamethadol	9605	I
Betacetylmethadol	9607	I
Betameprodine	9608	I
Betamethadol	9609	I
Betaprodine	9611	I
Dipipanone	9622	I
Hydroxypethidine	9627	I
Noracymethadol	9633	I
Norlevorphanol	9634	I
Normethadone	9635	I
Trimeperidine	9646	I
Phenomorphan	9647	I
1-Methyl-4-phenyl-4-propionoxypiperidine	9661	I
Tilidine	9750	I
Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide)	9811	I
Para-Fluorofentanyl	9812	I
3-Methylfentanyl	9813	I
Alpha-methylfentanyl	9814	I
Acetyl-alpha-methylfentanyl	9815	I
Ortho-fluorofentanyl N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide	9816	I

Controlled substance	Drug code	Schedule
Acetyl Fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide) .....	9821	I
Butyryl Fentanyl .....	9822	I
Para-Fluorobutyl Fentanyl .....	9823	I
4-Fluoroisobutyl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide) .....	9824	I
Methoxyacetyl Fentanyl 2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide .....	9825	I
Para-Chloroisobutyl Fentanyl .....	9826	I
Isobutyl Fentanyl .....	9827	I
Beta-hydroxyfentanyl .....	9830	I
Beta-hydroxy-3-methylfentanyl .....	9831	I
Alpha-methylthiofentanyl .....	9832	I
3-Methylthiofentanyl .....	9833	I
Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide) .....	9834	I
Thiofentanyl .....	9835	I
Beta-hydroxythiofentanyl .....	9836	I
Para-methoxybutyl fentanyl .....	9837	I
Ocfentanil .....	9838	I
Valeryl Fentanyl .....	9840	I
Tetrahydrofuran Fentanyl N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide .....	9843	I
Cyclopropyl Fentanyl .....	9845	I
Cyclopentyl fentanyl .....	9847	I
Fentanyl related-compounds as defined in 21 CFR 1308.11(h) .....	9850	I
Amphetamine .....	1100	II
Methamphetamine .....	1105	II
Lisdexamfetamine .....	1205	II
Phenmetrazine .....	1631	II
Methylphenidate .....	1724	II
Amobarbital .....	2125	II
Pentobarbital .....	2270	II
Secobarbital .....	2315	II
Glutethimide .....	2550	II
Nabilone .....	7379	II
1-Phenylcyclohexylamine .....	7460	II
Phencyclidine .....	7471	II
4-Anilino-N-phenethyl-4-piperidine (ANPP) .....	8333	II
1-Piperidinocyclohexanecarbonitrile .....	8603	II
Alphaprodine .....	9010	II
Cocaine .....	9041	II
Codeine .....	9050	II
Dihydrocodeine .....	9120	II
Oxycodone .....	9143	II
Hydromorphone .....	9150	II
Diphenoxylate .....	9170	II
Ecgonine .....	9180	II
Ethylmorphine .....	9190	II
Hydrocodone .....	9193	II
Levomethorphan .....	9210	II
Levorphanol .....	9220	II
Isomethadone .....	9226	II
Meperidine .....	9230	II
Meperidine intermediate-A .....	9232	II
Meperidine intermediate-B .....	9233	II
Meperidine intermediate-C .....	9234	II
Metazocine .....	9240	II
Methadone .....	9250	II
Methadone intermediate .....	9254	II
Dextropropoxyphene, bulk (non-dosage forms) .....	9273	II
Morphine .....	9300	II
Thebaine .....	9333	II
Levo-alphaacetylmethadol .....	9648	II
Oxymorphone .....	9652	II
Noroxymorphone .....	9668	II
Thiafentanil .....	9729	II
Racemethorphan .....	9732	II
Alfentanil .....	9737	II
Remifentanil .....	9739	II
Sufentanil .....	9740	II
Carfentanil .....	9743	II
Tapentadol .....	9780	II
Fentanyl .....	9801	II

The company plans to manufacture small quantities of the listed controlled substances to make reference standards which will be distributed to its customers.

Dated: June 12, 2018.

**John J. Martin,**

*Assistant Administrator.*

[FR Doc. 2018-13221 Filed 6-19-18; 8:45 am]

BILLING CODE 4410-09-P

## NATIONAL SCIENCE FOUNDATION

### Request for Information— Environmental Research and Education, National Security, and Economic Competitiveness

**AGENCY:** National Science Foundation.

**ACTION:** Notice of Request for Information.

**SUMMARY:** The purpose of this Request for Information (RFI) is to seek input from the public on possible future directions for fundamental environmental science and education. The RFI intends to gather views from external stakeholders on what environmental research and education is needed to further advance national security and economic competitiveness. NSF's Advisory Committee for Environmental Research and Education (AC ERE) will use the input to develop a report on these topics to inform NSF and the community.

**DATES:** Written comments must be submitted by August 20, 2018.

**ADDRESSES:** Responses will be submitted via online survey (<https://www.surveymonkey.com/r/ACERE-RFI-2018>). See the instructions in the **SUPPLEMENTARY INFORMATION** for guidelines.

**FOR FURTHER INFORMATION CONTACT:** Contact Leah Nichols, Executive Secretary for the AC ERE, at [lnichol@nsf.gov](mailto:lnichol@nsf.gov) for further information.

**SUPPLEMENTARY INFORMATION:** The National Science Foundation's Advisory Committee for Environmental Research and Education (AC ERE) invites your input on possible environmental research and education directions to further advance national security and economic competitiveness. The purpose of the AC ERE is to:

- Provide advice, recommendations and oversight concerning support for the NSF's environmental research and education portfolio;
- Be a base of contact with the scientific community to inform NSF of the impact of its research support and NSF-wide policies on the scientific community;

- Serve as a forum for consideration of interdisciplinary environmental topics as well as environmental activities in a wide range of disciplines;

• Provide broad input into long-range plans and partnership opportunities; and

- Provide advice about program management, overall program balance, and other aspects of program performance for environmental research and education activities.

The Committee has been interested broadly in fundamental environmental research and education that also has societal utility. It has recently focused its attention on two major topics where there is broad consensus on the importance of the research to date, but where significant research questions remain. These topics are at the nexus of environmental science and engineering with economic growth and competitiveness, and the relationship of environmental factors to national and human security. The Committee is particularly interested in approaches that promote convergent research across disciplines and sectors to address economic competitiveness and economic security.

To identify emerging research questions in these areas, the committee is reaching out to interested and knowledgeable members of the scientific community in all disciplines and interdisciplinary areas for their views. The AC ERE is also interested in the views of professionals who are directly involved in decision-making or operational activities in these areas, and who therefore can provide a very practical perspective on high-priority research and education topics.

The AC ERE invites individuals and groups of individuals to provide input on one or both of the topics described above via this link: <https://www.surveymonkey.com/r/ACERE-RFI-2018>.

The online submission form requires the following information:

1. Author name(s) and affiliation(s);
2. Valid contact email address;
3. Title of the response;
4. An abstract (200 words or less) summarizing the response; and
5. Checkbox to consent to allow the AC ERE to display the submitted information, consistent with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (<https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode>).

You will also be asked to identify whether your response focuses on questions in environmental research and education that are pertinent to (a)

economic growth and competitiveness, (b) national and human security, or (c) both topics. The submission form includes the following question prompts. Respondents may respond to all or any subset of these questions.

- What are the major environmental research priorities with the greatest potential to contribute to economic growth and competitiveness and/or national or human security/wellbeing? Priorities could, for example, include empirical, theoretical, or qualitative analyses, establishing baselines, and/or experimental studies. (500 words or less)

- What methodologies should be used for conducting such studies? Methodological recommendations could include the prospects for interdisciplinary and/or convergent research approaches, including modeling, theory, empirical, qualitative, and/or experimental studies. Methodological recommendations could also discuss the scope of studies, e.g. the balance between single-investigator studies and large teams. (500 words or less)

- What education (including formal and informal), research, and training opportunities—for students, postdoctoral researchers, and mid-career scientists—are needed? Opportunities might include interdisciplinary, team-based, or other innovative, value-added strategies for realizing higher levels of depth and breadth at the individual level, and/or expansion of the current environmental research community through inclusion of currently under-represented groups. (500 words or less)

- Beyond economic competitiveness and national security, what other high priority drivers of environmental science and education need attention? (200 words or less)

*Submissions must be received by 5:00 p.m. Eastern Time on August 20, 2018.* Respondents may edit their responses while completing the survey, but will not be able to save work in progress to complete later. Respondents will see a confirmation screen upon successful submission responses.

The committee and associated staff will read and analyze all responses received, and use them, in addition to its own background work, to develop a report on these topics to inform NSF and the community. It intends to publish this report by the end of 2018.

The AC ERE also anticipates making submissions publicly accessible through its website (<https://www.nsf.gov/ere/ereweb/advisory.jsp>). Authors who do not wish to have their full responses posted online may restrict access to the AC ERE and associated staff. However,